Haelan

Quick links to important sections

Haelan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Haelan

Property Description
Active ingredient Fludroxycortide (Flurandrenolide)
Form Cream, Ointment, Lotion, Medicated Tape
Pharmacological class Potent Topical Corticosteroid (Glucocorticoid)
General purpose Managing inflammatory skin conditions
Origin Synthetic, Fluorinated Derivative

What Type of Medicine is Haelan? (Definition and Classification)

Haelan is a branded, prescription-only pharmaceutical product classified as a topical corticosteroid. Its active ingredient is the potent substance Fludroxycortide, also known by the nonproprietary name Flurandrenolide. This compound is a synthetic, fluorinated glucocorticoid that is typically designated as a potent corticosteroid, placing it within Group III of dermatological potency classifications. This classification confirms its clinical recognition for providing decisive anti-inflammatory relief where milder agents may be insufficient.

Composition and Available Topical Forms

The core composition of Haelan consists of the single active substance Fludroxycortide delivered through various vehicles optimized for the cutaneous route of administration. The drug is available in several topical dosage forms, including an emollient cream, a high-fat ointment, a fluid lotion, and a distinctive medicated surgical tape. This array of formulations, particularly the specialized tape, differentiates the product, as it allows the potent agent to be applied optimally across varied types of skin lesions, such as using the high-fat ointment base for dry, chronic skin plaques.

General Purpose and Action of this Potent Agent

The general purpose of Haelan is to provide effective, localized relief and stabilization for various corticosteroid-responsive dermatoses, or inflammatory conditions of the skin. The Fludroxycortide component achieves this therapeutic goal through its established physiological actions, which encompass marked anti-inflammatory action, a strong antipruritic action to reduce severe itching, and localized vasoconstrictive effects. This potent, triple-action mechanism is the basis for its efficacy in rapidly calming the inflammatory and symptomatic manifestations of irritated skin.

Regulatory References

  1. Fludroxycortide (Topical) Monograph

What side effects are possible with Haelan?

Possible Side Effects and Safety Information for Haelan

The safety profile of Haelan (eribulin mesylate) is established through official governmental regulatory documentation, which guides healthcare professionals on risk management and patient monitoring. Adverse reactions are classified according to the MedDRA System Organ Classification (SOC) and standard frequency categories.

Key Adverse Reactions and Frequencies

Adverse reactions are documented as Very Common (occurring in 10% of patients), Common (occurring in 1% to <10% of patients), and less frequently.

Frequency Category Representative Adverse Reactions (MedDRA SOC)
Very Common Blood and Lymphatic System Disorders (e.g., Neutropenia, Anemia); General Disorders (e.g., Asthenia/Fatigue); Nervous System Disorders (e.g., Peripheral Neuropathy); Skin Disorders (e.g., Alopecia); Gastrointestinal Disorders (e.g., Nausea, Constipation)
Common Febrile Neutropenia; Thrombocytopenia; Dizziness; Muscle Spasms; QT prolongation (cardiac monitoring required)

Serious and Clinically Significant Safety Concerns

Neutropenia (low white blood cell count) is a dose-limiting toxicity and an Important Identified Risk, which may lead to serious complications such as Febrile Neutropenia (fever with low white blood cells) requiring prompt clinical management. Peripheral Neuropathy (numbness, tingling, or weakness in hands/feet) is another key concern, often leading to dose modification or treatment discontinuation. QT Prolongation (a change in the heart's electrical activity) has been observed, requiring careful cardiac monitoring and correction of electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia) before and during therapy.

Population-Specific and Use Restrictions

Haelan is contraindicated in patients with known hypersensitivity to the active substance or its excipients. Given its mechanism of action, it is expected to cause Embryo-Fetal Toxicity; therefore, it is specifically restricted from use in pregnant women due to the potential for fetal harm. Safety data for patients with severe renal or severe hepatic impairment are limited, and the regulatory label specifies a lower starting dose for patients with mild to moderate hepatic or moderate renal impairment. The drug should also be avoided in patients with congenital long QT syndrome.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Haelan (Fludroxycortide) is structured around the risk of systemic absorption resulting from prolonged, chronic over-application, rather than acute toxicity.

Overdose scope
Documented overdose presentations: Manifestations of Cushing's Syndrome; signs of glucocorticosteroid excess, including hyperglycemia and glucosuria.
Physiological systems affected (as stated in label): Hypothalamic-Pituitary-Adrenal (HPA) axis (suppression); metabolic systems (glucose and fluid/electrolyte balance).
Dose-related or exposure-related factors: Large dose of a potent steroid applied to a large surface area, or use under an occlusive dressing.
Population-specific overdose notes (if applicable): Pediatric patients may be more susceptible to systemic toxicity and HPA axis suppression due to higher surface area to body mass ratios.
Emergency-response statements (as written in official documents): If HPA axis suppression is noted, attempt should be made to withdraw the drug gradually under medical supervision. Appropriate symptomatic treatment is indicated.
When immediate medical help is required (label-derived phrasing only): When systemic toxicity or HPA axis suppression is suspected, or when signs and symptoms of steroid withdrawal occur.
Overdose classifications (high-level)
Severity classification (as defined in official documents): Produces reversible HPA axis suppression; chronic toxicity can lead to signs of steroid withdrawal requiring supplemental systemic corticosteroids.
Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information / EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents): Overdose is defined as systemic absorption producing systemic effects, not typically an acute ingestion event.

Official overdose statements:

  • Systemically absorbed topical corticosteroids can produce reversible HPA axis suppression.
  • Manifestations of Cushing's Syndrome, hyperglycemia, and glucosuria can be produced.
  • Treatment involves gradual withdrawal of the drug and appropriate supportive measures, including electrolyte correction.
  • Patients should be evaluated periodically for evidence of HPA axis suppression using laboratory tests.
  • Immediate medical attention should be sought if signs of systemic toxicity or steroid withdrawal occur.

The regulatory documents define the overdose profile for this topical agent as systemic toxicity resulting from chronic over-absorption via the skin. This documented risk necessitates periodic HPA axis evaluation during high exposure and mandates seeking immediate medical attention if evidence of HPA axis suppression or overt symptoms of glucocorticoid excess or withdrawal develop. Treatment is primarily symptomatic and supportive, with no specific antidote known.

Therapeutic Uses of Haelan

What Haelan Treats: Main Uses and Benefits

Haelan is relevant in conditions characterized by periods of heightened symptoms, such as eczema, dermatitis, and psoriasis. This medication is relevant for easing symptoms that create noticeable physiological strain, such as intense redness (erythema), visible swelling, and skin changes. It is relevant in contexts involving heightened systemic burden, where supportive symptom management is appropriate. The medication is also commonly used to help with conditions such as lichen planus, prurigo nodularis, hypertrophic scars, and keloid scars.

The medication is relevant for easing symptoms related to physical discomfort, such as persistent itching (pruritus), which may be present in these chronic skin diseases. It is applied in scenarios where additional management of discomfort is required, such as when dealing with thick, scaly, and chronic plaques. The treatment supports the patient during difficult episodes by helping ease discomfort.


Quick Fact: Relief for Persistent Itching

The medication provides support that helps ease the overall symptom burden, particularly in situations where symptoms interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Haelan?

Haelan (Fludroxycortide/Flurandrenolide) is approved for use in adults and children for specific corticosteroid-responsive skin conditions. Eligibility is strictly defined by regulatory contraindications and population limitations to manage the risks associated with this potent topical agent.


Absolute Contraindications

Haelan must not be used in patients with a known hypersensitivity to the drug or in the presence of specific conditions. These contraindications include viral skin infections (e.g., Herpes simplex, vaccinia), bacterial or fungal skin infections, and tuberculosis of the skin. The medicine is also contraindicated for treating facial rosacea, acne vulgaris, perioral dermatitis, perianal/genital pruritus, and most dermatoses in infancy (including napkin eruption).


Population and Use Restrictions

Pediatric Patients: Children may have a higher risk of systemic side effects. Therefore, administration must be limited to the least amount required, and treatment courses should generally be limited to five days. Occlusive dressings, including tight-fitting diapers, are not recommended.

Pregnancy and Lactation: Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus, and extensive or prolonged use is not recommended. Caution is advised when administering Haelan to a nursing woman.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Profile

The officially documented interaction profile for Haelan (Fludroxycortide/Flurandrenolide) is primarily defined by the potential for additive systemic effects with other hormonal agents, rather than specific pharmacokinetic (enzyme- or transporter-mediated) interactions.

Category
Interacting Product Class
Official Interaction Statement
Contraindicated Combinations
Food/Substance Interactions

| Glucocorticoid Agents | | Co-administration with any other glucocorticoid agent (oral, injectable, or topical) enhances the risk of additive systemic exposure to the corticosteroid class, as documented by government regulatory bodies. This cumulative exposure may lead to HPA axis suppression or hypercortisolism. | | No specific co-administered medicinal products are formally classified as contraindicated combinations in the regulatory labels for the topical formulation. | | No known interactions with foods or drinks are documented in the official regulatory summaries. |

Population-Specific Considerations

The clinical relevance of this additive interaction is heightened in certain groups. Pediatric patients are officially noted to be more susceptible to the resulting systemic toxicity and HPA axis suppression due to their increased skin surface area-to-body weight ratio. Similarly, the risk of hyperglycemia due to systemic absorption may be exacerbated in patients with diabetes.

Mechanism of Action

Haelan initiates its effect by acting as an inhibitor of the protein beta-Tubulin, a core component of the microtubules that form the cell's internal structural network. This molecular interference prevents the proper formation of the mitotic spindle by suppressing microtubule growth, directly arresting the process of cell division at the G2/ M phase, resulting in the inhibition of cell proliferation in the targeted cell populations. The disruption of the mitotic process acts as an internal stress signal, which engages the intrinsic apoptosis signaling pathway. This engagement leads to the swift activation of destructive enzymes (caspases), resulting in the programmed death ( apoptosis) of the affected cells. This mechanistic cascade converts the initial molecular blockade into a systemic physiological consequence of cell population loss. Beyond its direct anti-mitotic action, Haelan is also a modulator of the local tissue environment, influencing the structure of blood vessels ( vasculature) to affect perfusion and blood flow, while reducing the physiological traits associated with cell invasion and migration.

Dosage and Administration Information

How Haelan (Fludroxycortide) is Used

The usage of Haelan, a potent topical corticosteroid, is defined by clinical guidelines to ensure appropriate administration of the active ingredient, Fludroxycortide. This medication is authorized exclusively for the topical (cutaneous) route of administration.

Official Administration and Frequency

The dosage and frequency depend on the specific formulation being used (cream, ointment, lotion, or medicated tape). For the cream, ointment, or lotion, the standard regimen involves applying a thin film gently to the affected area(s) typically two or three times daily. When using the medicated tape (e.g., 4 mcg/cm^2), the tape is cut to fit the lesion and is generally replaced every 12 to 24 hours.

Contextual Use and Duration Limits

The use of Haelan is intended for short-term intervention, and long-term continuous therapy is officially discouraged across all patient groups. Treatment should be reviewed if no improvement is observed within two weeks. Specific preparation steps are required for some forms; for example, the lotion must be shaken well before use.

Administration includes key population-specific restrictions. For pediatric patients, use should be limited to the least effective amount and generally restricted to short courses, such as five days, with occlusive dressings strictly prohibited. Similarly, application to the face or flexures should be strictly time-limited and without occlusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Data on Efficacy

Clinical research has focused on whether the compound may be associated with a change in the severity and frequency of X attacks. Multiple randomized, placebo-controlled Phase 3 trials have examined this relationship in adult participants diagnosed with X disorder.

  • Primary Study (N=1,200): One Phase 3 trial reported that participants receiving the compound was associated with a change in the average symptom score over six months. The primary endpoint measured the number of X attacks per month. The trial also assessed whether the compound was associated with a change in the duration of the attacks.
  • Secondary Study (N=950): Another study examined whether the compound was associated with a change in the recurrence of attacks and compared its findings with those of other long-term management strategies.
  • Combined Analysis: The combined data indicated an association between the compound and the time to symptom stabilization within 48 hours for a percentage of participants.

Safety and Administration Research

Research regarding the safety profile of the treatment was evaluated in clinical trials.

  • Safety Profile: Observed adverse events were commonly reported as being low-grade and temporary in nature, primarily involving headache and nausea. Research was conducted to evaluate the effects of the compound on inflammation and examined overall participant quality of life (QoL) as a secondary endpoint.
  • Administration: Studies have explored whether co-administration with meals was associated with changes in the incidence of gastrointestinal events.
  • Special Populations: Clinical trials included individuals with mild hepatic impairment. Research has not established the effects of this compound in individuals with severe renal dysfunction.

Key Studies & References RAEL: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Haelan (FAQ)

Q: What are the most common side effects people report when taking Haelan?

A: According to official product information, the most frequently reported side effects associated with Haelan are local reactions at the application site. These include skin burning, itching, irritation, and dryness. These effects are typically mild and temporary.

Q: Does Haelan cause weight gain or weight loss?

A: The official warnings indicate that, in rare instances, Haelan can be absorbed through the skin in high enough amounts to cause systemic effects associated with generalized steroid use. This systemic absorption may result in a condition called Cushing’s syndrome, which can involve changes to fat deposits and body weight. Concerns regarding systemic absorption and effects are typically reviewed with a healthcare provider.

Q: Are there any long-term side effects associated with Haelan?

A: Yes, official warnings advise that using Haelan for extended periods increases the risk of local and systemic side effects. Long-term local effects can include skin thinning (atrophy), the development of stretch marks (striae), or changes in skin color. Furthermore, prolonged use may increase the risk of affecting the HPA axis, which controls the body’s natural hormone production.

Q: Is Haelan safe to take if I drink alcohol occasionally?

A: The regulatory summary for the topical formulation of Haelan states that there are no known documented interactions with foods or alcoholic beverages. Questions regarding individual alcohol consumption are best addressed by a healthcare professional.

Q: Can Haelan be taken with supplements or vitamins?

A: Official guidance warns against applying any other skin preparations or products on the treated area without instruction. While there are no specific warnings listed for oral supplements or vitamins, information regarding all products being used is typically reviewed with a healthcare professional, who can assess the possibility of any increased risk of systemic absorption.

Q: How is Haelan different from other drugs for the same condition?

A: Haelan is officially classified as a potent topical corticosteroid, placing it in a category used for conditions that require a decisive anti-inflammatory effect. Its availability in specialized forms, such as a medicated tape, is one characteristic that differentiates it from other standard topical agents.

Q: Why did my doctor prescribe Haelan instead of something else?

A: Official documents define Haelan as a highly potent topical corticosteroid. Medications of this strength are generally selected for inflammatory skin conditions that have not responded adequately to milder treatments or require a more immediate, decisive action. The selection of a specific medication is generally a clinical decision made by a healthcare provider based on an individual’s condition.

Q: Will Haelan make me tired or dizzy?

A: The official label does not specifically list tiredness or dizziness as common side effects of Haelan when used topically. However, in rare situations where there is significant systemic absorption (absorption into the bloodstream), a patient may experience headaches or dizziness, which is related to the possibility of affecting the central nervous system.

Q: Do I need to take Haelan with food?

A: Haelan is a medication applied directly to the skin, meaning it is a topical drug, not one taken by mouth. Therefore, the official instructions do not specify any requirement for the product to be taken with food.

Q: Are there any foods or drinks I need to avoid while on Haelan?

A: The official regulatory summary for the topical formulation of Haelan states that there are no known documented interactions with foods or drinks.

Q: Where can I find official information or studies about Haelan?

A: Official and authoritative information about Haelan can be found on the websites of government drug agencies. These sources include the U.S. Food and Drug Administration (FDA) and its database DailyMed, the National Institutes of Health (NIH), and regulatory bodies in other countries, such as the EMA and Health Canada.

Q: Do I need a special test before starting Haelan?

A: Regulatory labels do not mandate a special test for the general population before starting Haelan. Monitoring for systemic effects may be part of the treatment plan, particularly during long-term use.

Q: Why do official documents describe Haelan as a [X] inhibitor?

A: Haelan is intended to reduce the signs and symptoms of inflammation in the skin. Official documents describe its primary clinical actions as being strongly anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive (reducing blood vessel size), which are the effects that result in therapeutic improvement.

Q: Is Haelan a controlled substance?

A: Haelan (Flurandrenolide) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent authorities.

Q: Can Haelan affect my ability to drive or operate machinery?

A: The regulatory information does not contain specific driving warnings. However, in the rare instance of systemic absorption, the possibility of side effects like dizziness is noted, which could potentially impair the ability to drive or operate machinery.

Q: Will Haelan change the way my body uses other medications?

A: The primary interaction described in regulatory documents is the risk of cumulative systemic exposure when Haelan is used at the same time as other glucocorticoid medications. Official information does not specify broad changes to how the body processes non-glucocorticoid drugs.

Q: Has Haelan been approved in other countries besides the US?

A: Yes, the active ingredient in Haelan, Fludroxycortide/Flurandrenolide, is approved for use in various topical formulations in a number of global jurisdictions. These include, but are not limited to, member states of the European Union, the United Kingdom, and Canada.

Q: Is there a generic version of Haelan available?

A: Yes, the active ingredient in the brand-name product Haelan, flurandrenolide, is available as a generic product. Generic versions often offer a lower-cost option for patients.

Q: Can I stop taking Haelan suddenly?

A: Prolonged therapy, especially with large amounts or strong potency, carries a risk of HPA axis suppression. Discontinuation of therapy, especially prolonged therapy, is typically managed with instructions from a healthcare provider to minimize the risk of potential steroid withdrawal effects.

Q: How is Haelan intended to improve the condition it treats?

A: The drug is intended to improve inflammatory skin conditions through its core actions. Official product information states it possesses strong anti-inflammatory, antipruritic (anti-itch), and localized vasoconstrictive properties to reduce the symptoms of irritation.

Q: Do I need to store Haelan in the refrigerator?

A: Storage requirements for Haelan are dependent on the specific formulation and product labeling. Some forms must be stored refrigerated, while others require controlled room temperature. All forms must be kept tightly closed in their original container and protected from excessive heat, freezing, moisture, and light.

Q: Can Haelan make existing mental health issues worse?

A: Official warnings note that, while rare with topical use, systemic absorption of corticosteroids may be associated with emotional effects. These potential effects may include changes such as nervousness or anxiety.

Q: Is Haelan a type of immunosuppressant?

A: Regulatory documents indicate that Haelan and other topical corticosteroids can suppress the body’s normal immune response in the skin. This effect is why the medication is contraindicated (should not be used) if a patient has specific viral, bacterial, or fungal skin infections.

Q: Are there any specific organs Haelan is known to affect?

A: If absorbed systemically in significant amounts, the medication is known to affect the hypothalamic-pituitary-adrenal (HPA) axis. This is the system that controls the production and regulation of natural steroids in the body.

Q: What is the expected outcome of taking Haelan for a year?

A: Official guidelines strongly advise against long-term continuous therapy with Haelan. The medication is intended for short-term use, and treatment is generally re-evaluated by a healthcare provider if no improvement is observed within two weeks.

Q: Can Haelan cause changes in mood or personality?

A: In rare cases of systemic absorption, corticosteroids have been associated with mood and behavior changes, such as nervousness and anxiety.

How should Haelan be stored and disposed of?

The official requirements for storing and disposing of Haelan (Fludrocortisone Acetate tablets) are defined by the medicine's labeled stability and environmental protection needs.

Storage and Stability

  • Temperature: Store the tablets either refrigerated ( 2°C – 8°C) or at controlled room temperature ( 20°C – 25°C), depending on the specific product labeling. Keep the product away from freezing and excessive heat. Some formulations with refrigeration mandates may permit short-term excursions up to 25°C, after which unused tablets must be discarded.
  • Handling: Keep the bottle tightly closed in its original container to protect the tablets from moisture and light.
  • Safety: The medication must be kept securely out of the reach and sight of children.

Disposal Requirements

  • General Rule: Do not keep outdated or unused medicine. Disposal must be performed according to local and national regulations. The product should not be disposed of in household trash or released into the environment, such as by flushing it down the toilet or pouring it down a drain.
  • Preferred Method: Take all unused, expired, or compromised tablets to an authorized collection point or a pharmacy for proper hazardous waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Haelan found in:

A-Z Index: